CoChat
Sign Up
Cited by 164Attention Deficit Hyperactivity DisorderNicotinic Acetylcholine Receptors StudyNeurotransmitter Receptor Influence on Behavior

Neuronal nicotinic receptor agonists for the treatment of attention-deficit/hyperactivity disorder: Focus on cognition

Open access
Wilens, Timothy E., Decker, Michael W.·2007·Biochemical Pharmacology
DOI 10.1016/j.bcp.2007.07.002PMC PMC2974320
Open this paper in CoChat — free account

Abstract

Attention deficit/hyperactivity disorder (ADHD) is the most commonly diagnosed neurobehavioral disorder in children and adolescents, and in about half of these patients, significant symptomology continues into adulthood. Although impulsivity and hyperactivity are the most salient features of ADHD, cognitive deficits, particularly impairments in attention and executive function, are an important component, particularly in adolescents and adults, with over 90% of adults seeking treatment for ADHD manifesting cognitive dysfunction. Currently available medications treat the core ADHD symptoms but typically do not adequately address cognitive aspects of ADHD, underscoring the need for new therapeutics. Dopamine and norepinephrine are hypothesized to be particularly important in ADHD, but there is emerging evidence that cholinergic neurotransmission, particularly involving neuronal nicotinic acetylcholine receptors (nAChRs), may play a role in the pathophysiology of ADHD. Nicotine has demonstrated procognitive effects in both humans and experimental animals and has produced signals of efficacy in small proof-of-concept adult ADHD trials. Although adverse effects associated with nicotine preclude its development as a therapeutic, a number of novel nAChR agonists with improved safety/tolerability profiles have been discovered. Of these, ABT-418 and ABT-089 have both demonstrated signals of efficacy in adults with ADHD. Notably, tolerability issues that might be expected of a nAChR agonist, such as nausea and emesis, were not observed at efficacious doses of ABT-089. Further understanding of the effects of novel neuronal nAChR agonists on specific aspects of cognitive functioning in ADHD is required to assess the full potential of this approach.

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1016/j.bcp.2007.07.002

Cites

174 of 174 references verified0 citation errors · 0 not checkable

Statistics

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

  • Some evidence supports the view that α4β2* nAChR compounds may be useful for treating the cognitive symptoms of ADHD, schizophrenia and aging.

    “Although the clinical evidence remains limited, some evidence supports the view that such compounds may be useful for treating the cognitive symptoms of ADHD, schizophrenia and aging (Dunbar et al, 2007; Wilens et al, 1999, 2006; Wilens and Decker, 2007; Potter et al, 1999).”

    From Modes and models of forebrain cholinergic neuromodulation of cognition (2011) · cites this paper as Wilens and Decker, 2007

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Cites

Flagged first, then by citations

Research works printed but not linked: 9

  1. [5]Weiss G. Child and Adolescent Psychiatric Clinics of North America. W.B. Saunders Company; Philadelphia PA: 1992. Attention-Deficit Disorder. [Google Scholar]
  2. [27]Lahey BB. Analysis of DSM-IV Field Trials. 1992. [Google Scholar]
  3. [33]Faraone SV, Biederman J, Monuteaux M, Seidman L. Attention deficit hyperactivity disorder and learning disability: A prospective four year follow-up study. J Atten Disord. 2001;3:23–25. [Google Scholar]
  4. [45]Seidman L. Neuropsychological testing. In: Tasman A, Kay J, Lieberman J, editors. Psychiatry. W. B. Saunders Company; 1997. pp. 498–508. [Google Scholar]
  5. [47]Matochik J, Rumsey J, Zametkin A, Hamburger S, Cohen R. Neuropsychological correlates of familial attention-deficit hyperactivity disorder in adults. Neuropsychiatry Neuropsychol Behav Neurol. 1996;9:186–191. [Google Scholar]
  6. [67]Fischer M. Persistence of ADHD into adulthood: It depends on whom you ask. The ADHD Report. 1997;5:8–10. [Google Scholar]
  7. [68]Spencer T. A controlled, long-term trial of methylphenidate in the treatment of adults with ADHD: preliminary data. Annual meetings of the American Psychiatric Association; Philadelphia, PA. May 2002. [Google Scholar]
  8. [73]Brown R, Sawyer M. Short-term cognitive and behavioral effects of psychotropic medications. In: Brown R, Sawyer M, editors. Medications for School-Aged Kids. New York, NY: Guilford; 1998. pp. 29–61. [Google Scholar]
  9. [162]Man K, Parikh V, Decker MW, Sarter M. Neuroscience Meeting Planner. Atlanta, GA: Society for Neuroscience; 2006. Differential cholinergic “footprints” evoked by nicotine- and the a4β2*-selective partial agonist ABT-089 in prefrontal cortex. Program No. 163.7. [Google Scholar]

Cited by

Sorted by citations

Related

Authors
Wilens, T. E., & Decker, M. W.
Affiliations
Massachusetts General Hospital (US)
Corresponding author
Wilens, Timothy E.
ORCID
Venue
Biochemical Pharmacology
Publisher
Elsevier BV
Published
2007-10
Volume
74
Issue
8
Pages
1212-1223
ISSN
0006-2952 (ISSN-L)
DOI
10.1016/j.bcp.2007.07.002
PMC
PMC2974320
OpenAlex
W2093484941
Cited by
164
References
174
Citations by year
2026: 2 · 2025: 7 · 2024: 4 · 2023: 10 · 2022: 4 · 2021: 2 · 2020: 2 · 2019: 6 · 2018: 6 · 2017: 4 · 2016: 12 · 2015: 10 · 2014: 15 · 2013: 11 · 2012: 8
FWCI
1.95
Type
journal article
Language
en
Open access
Licence
www.elsevier.com/tdm/userlicense/1.0/ (tdm)
Locations
  • Biochemical Pharmacology (publishedVersion)
  • PubMed (publishedVersion)
  • Europe PMC (PubMed Central) (acceptedVersion)
  • PubMed Central (acceptedVersion)
Funders
National Institute on Drug Abuse (2 R01 DA12945-06, K24DA016264, 5 K24 DA01624-02, R01DA012945)
Topics
  • Health Sciences › Medicine › Psychiatry and Mental health › Attention Deficit Hyperactivity Disorder
  • Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Nicotinic Acetylcholine Receptors Study
  • Life Sciences › Neuroscience › Cellular and Molecular Neuroscience › Neurotransmitter Receptor Influence on Behavior
Keywords
attention deficit hyperactivity disorder, neuronal nicotinic acetylcholine receptors, nicotinic agonists, cognitive impairment, attention, executive function, nicotine, ABT-418, cholinergic neurotransmission, adult ADHD, tolerability
MeSH terms
Animals, Attention Deficit Disorder with Hyperactivity, Cognition, Humans, Isoxazoles, Synaptic Transmission, Pyridines, Pyrrolidines, Receptors, Nicotinic, Nicotinic Agonists

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review